Loading...

SOHO 2026 Annual Meeting

This website and third-party tools we use rely on cookies for the best user experience. By selecting "I agree", you agree to cookie usage as described in our Privacy Policy.

1,267 posters, 47 videos, 13 topics, 4 sessions, 853 authors

ePostersLive by SciGen Technologies S.A. All rights reserved.

SOHO 2026 Annual Meeting

September 9 - 12, 2026 | George R. Brown Convention Center, Houston, Texas

Home Posters by Code Posters by Title Authors Affiliations Topics Sessions Videos Audios Previous meetings

Authors

Showing 7 results for author "Edward Mwarangu".

Back to authors

Thumbnail for Comparative Pharmacovigilance of CD20-Directed Bispecific Antibodies in B-Cell Lymphoma: A FAERS Observational Study

ABCL - 100

Comparative Pharmacovigilance of CD20-Directed Bispecific Antibodies in B-Cell Lymphoma: A FAERS Observational Study

Edward Mwarangu

Poster Presenter: Edward Mwarangu

Thumbnail for Have Survival Gains in Acute Myeloid Leukemia Been Equitable? Persistent Racial Disparities in a SEER Analysis (2000-2023)

AML - 085

Have Survival Gains in Acute Myeloid Leukemia Been Equitable? Persistent Racial Disparities in a SEER Analysis (2000-2023)

Edward Mwarangu

Poster Presenter: Edward Mwarangu

Thumbnail for Phenotype-Specific Safety Differences Between Gilteritinib and Midostaurin in AML: A FAERS Analysis Highlighting Differentiation Syndrome Signal

Copyright © 2015-2026, ePostersLive® SciGen is a registered trademark of SciGen Technologies S.A. Patent pending.

AML - 103

Phenotype-Specific Safety Differences Between Gilteritinib and Midostaurin in AML: A FAERS Analysis Highlighting Differentiation Syndrome Signal

Edward Mwarangu

Poster Presenter: Edward Mwarangu

Thumbnail for Phenotype-Specific Safety Reporting Signals of Asciminib Versus Second- and Third-Generation Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia: A FAERS Disproportionality Analysis

CML - 115

Phenotype-Specific Safety Reporting Signals of Asciminib Versus Second- and Third-Generation Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia: A FAERS Disproportionality Analysis

Edward Mwarangu

Poster Presenter: Edward Mwarangu

Thumbnail for Survival and Early Mortality Disparities in Classical Hodgkin Lymphoma Across the Immunotherapy Era: A SEER Analysis (2010-2022)

HL - 092

Survival and Early Mortality Disparities in Classical Hodgkin Lymphoma Across the Immunotherapy Era: A SEER Analysis (2010-2022)

Edward Mwarangu

Poster Presenter: Edward Mwarangu

Thumbnail for Target-Specific Toxicity Phenotypes of BCMA- vs GPRC5D-Directed Bispecific Antibodies in Multiple Myeloma: A FAERS Analysis

MM - 106

Target-Specific Toxicity Phenotypes of BCMA- vs GPRC5D-Directed Bispecific Antibodies in Multiple Myeloma: A FAERS Analysis

Edward Mwarangu

Poster Presenter: Edward Mwarangu

Thumbnail for Survival Outcomes and Racial Disparities in Adolescent and Young Adult Classic Philadelphia-Negative Myeloproliferative Neoplasms: A SEER Analysis, 2000-2023

MPN - 088

Survival Outcomes and Racial Disparities in Adolescent and Young Adult Classic Philadelphia-Negative Myeloproliferative Neoplasms: A SEER Analysis, 2000-2023

Edward Mwarangu

Poster Presenter: Edward Mwarangu

ePosters in

Topics Sessions

Acute Lymphoblastic Leukemia (ALL)(71)Acute Myeloid Leukemia (AML)(230)Aggressive B-Cell Lymphoma (ABCL)(114)Cellular Therapy (CT)(128)Chronic Lymphocytic Leukemia (CLL)(110)Chronic Myeloid Leukemia (CML)(55)Hodgkin Lymphoma (HL)(54)Indolent B-Cell Lymphoma (IBCL)(47)Mantle Cell Lymphoma (MCL)(23)Multiple Myeloma (MM)(234)

Previous 1 2 Next

Sponsors